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Objective: To evaluate interoperator differences in cancer detection and complication rates using trans-
rectal ultrasound (TRUS)-guided prostate biopsies. We also analyzed whether there was a correlation
between the experience of the operator and the cancer detection rate.
Materials and methods: Medical records of 1879 patients who underwent a TRUS-guided prostate biopsy
between 2005 and 2009 were retrospectively reviewed. Among them, 1496 patients who underwent
a ﬁrst biopsy without previous prostate surgery were selected for the analysis. Five urology residents
performed 327, 351, 218, 332, and 268 biopsies, respectively. Cancer detection rates were analyzed by
comparing the initial 20 and 100 patients with the ﬁnal 20 and 100 patients. Patients were subdivided
into two groups: prostate-speciﬁc antigen (PSA) of approximately 4e10 and >10 ng/mL. Prostate cancer
(CaP) detection and complication rates were compared among operators.
Results: Cancer was detected in 541 patients (36%). The operators performed a median of 403 (range:
approximately 277e436) transrectal sono-guided prostate biopsies with CaP detection rates of
approximately 33.9e42.2% (p ¼ 0.243). Among different operators, we found no differences in cancer
detection rates for the initial 100 or ﬁnal 100 patients, even when separating patients into PSA > 10 ng/
mL and 4 < PSA < 10 ng/mL groups. But signiﬁcant individual variations in CaP-positive rates (p ¼ 0.046)
were observed in the ﬁrst 20 biopsies for patients with PSA > 10 ng/mL receiving a TRUS biopsy;
however, variable PSA levels in different groups of patients may have been responsible for this ﬁnding.
There were no differences in complication rates among the different operators for the initial 20 and ﬁnal
20 biopsies or for the initial 50 and ﬁnal 50 biopsies.
Conclusion: No clinically signiﬁcant differences in CaP detection existed among operators performing
TRUS-guided prostate biopsies. Complication rates did not differ among the operators. A TRUS-guided
prostate biopsy is a rapidly learned technique and is a good diagnostic tool for CaP detection.
Copyright  2012, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Before the availability of prostate-speciﬁc antigen (PSA) testing,
prostate cancer (CaP) was often detected at advanced and less-
curable stages. The utilization of PSA has led to earlier detection
of organ-conﬁned CaP. During the early stages of CaP, patients can
be relatively symptom free, and a prostate biopsy may be recom-
mended if the PSA level is abnormal or if a palpable nodule is found
during a digital rectal examination (DRE).partment of Surgery, Taipei
2, Taipei 11217, Taiwan.
ciation. Published by Elsevier TaiwA transrectal ultrasound (TRUS)-guided biopsy is the standard
procedure for diagnosing CaP, and is a tool for diagnosing smaller or
atypically located tumors, which cannot be palpated on a DRE.1
Several CaP predictors were studied, such as procured cores and
PSA levels. In this study, we evaluated whether the operator is an
independent factor in CaP detection, and whether complication
rates decrease when operators become skilled in this procedure.
2. Materials and methods
From 2006 to 2009, 2748 TRUS-guided biopsies were performed
at our institution. Among these, 1496 patients received their ﬁrst
TRUS biopsy and were included in the study. The following data
were obtained by retrospective chart review: age, PSA level, TRUS-
calculated prostate volume, pathological diagnosis, Gleason grade,an LLC. Open access under CC BY-NC-ND license.
Table 1
Demographic data of patients examined by different operators.
Operator p
1 2 3 4 5
No. of biopsies 327 351 218 332 268 e
Malignancy (%) 118 (36.1) 119 (33.9) 75 (34.4) 116 (34.9) 113 (42.2) 0.206
Median age (years) 75 (w55e89) 76 (w49e88) 75 (w47e89) 76 (w43e86) 76 (w42e86) 0.107
Median prostate size (cm3) 38.8 (w10.0e142.0) 36.0 (w13.0e143.2) 47.0 (w11.2e155.0) 39.9 (w16.7e167.2) 35.9 (w10.2e130.5) 0.103
PSA (%) e e e e e 0.244
w4e10 ng/dL (%) 183 (59) 173 (56) 112 (54) 181 (58) 130 (49) e
>10 ng/dL (%) 126 (41) 138 (44) 95 (46) 139 (42) 138 (51) e
Median PSA (ng/mL) 8.5 (w0.5e949) 8.5 (w0.4e988) 9.1 (w0.85e850) 8.5 (w0.4e9221) 9.6 (w0.4e9442) 0.244
Abnormal DRE (%) 51.1 56.1 52.8 55.4 54.5 0.700
Gleason score  7 (%) 71 (60.2) 80 (67.2) 45 (60.0) 73 (62.9) 79 (69.9) 0.409
PSA ¼ prostate-speciﬁc antigen; DRE ¼ digital rectal examination.
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residents, with 12 samples per biopsy (six from lateral cores and six
from medial cores, random biopsy). An evacuation enema was
given, and 80 mg gentamycin was given before the procedure, with
1 g cefazolin replacing gentamycin if a deterioration in renal
function was noted. All operators used the same equipment to
perform the procedure (side-ﬁring probe MG1522, MN series 1816
magnum core tissue biopsy needle, bard), and biopsy results were
interpreted by the same group of pathologists.
Patients were categorized according to their PSA levels as either
approximately 410 or >10 ng/mL, and the CaP detection and
complication rates for these two groups were analyzed by the
various operators. The ﬁrst and last 20, and the ﬁrst and last 100
patients’ CaP detection rates by the same operator and different
operators were also analyzed.
Complications of the TRUS-guided biopsy were deﬁned by the
occurrence of acute urinary retention or urinary tract infection
(UTI) that required hospitalization, but did not include minor
complications such as hematuria and rectal bleeding. We divided
patients into groups with prostate sizes of >45 and <45 cm3, and
compared complication rates between the ﬁrst and last 20,and
between the ﬁrst and last 50 patients. The prostate size (in cm3)
was measured using the ellipsoid formula: by multiplying the
largest anteroposterior (height), transverse (width), and cepha-
locaudal (length) prostate diameters by 0.52.
Categorical variables between operators were compared using
Pearson’s Chi-square and continuous variable KruskaleWallis tests
and analysis of variance.
3. Results
In total, 1496 patients receiving a TRUS-guided biopsy of the
prostate for the ﬁrst time were selected for the analysis. FiveTable 2




First 100 pts. (%) 42 (42) 36 (36)
Last 100 pts. (%) 32 (32) 37 (37)
First 100 biopsies
PSAw4e10 ng/dL (%) 14/52 (26.9) 10/51 (19.6)
PSA > 10 ng/dL (%) 24/42 (57.1) 24/38 (63.2)
Last 100 biopsies
PSAw4e10 ng/dL (%) 9/48 (18.8) 11/47 (23.4)
PSA > 10 ng/dL (%) 23/45 (51.1) 25/46 (54.3)
PSA ¼ prostate-speciﬁc antigen.urology residents performed a median of 327 (range: approxi-
mately 218e351) TRUS biopsies. The overall CaP predictive value
was 36.2% without signiﬁcant differences among operators (range:
approximately 33.9e42.2%, p ¼ 0.243).
Patient demographics for each operator are listed in the
Table 1. The median age, median PSA value, median prostate
size, and abnormal DRE percentage did not differ between
groups.
Overall cancer detection rates ranged between 33.9% and 42.2%,
and Gleason scores of >7 accounted for approximately 60.2e69.9%
(p ¼ 0.409) (Table 1). Among different operators, we found no
differences in cancer detection for the ﬁrst 100 or last 100 patients,
even if we separated them into groups by PSA scores of
PSA > 10 ng/mL, 4 ng/mL < PSA < 10 ng/mL (Table 2). Although no
signiﬁcant differences in cancer detection rates were found
between the ﬁrst 20 and last 20 patients receiving a prostate biopsy
among the different operators, there was signiﬁcant individual
variation in CaP-positive rates (p ¼ 0.046) for the ﬁrst 20 patients
with a PSA value of >10 ng/mL receiving a TRUS-guided biopsy
(Table 3).
The overall complication rate was 2.0%, and no signiﬁcant
difference was noted among operators (p ¼ 0.289). When we
compared the ﬁrst 20 and 50 patients with the last 20 and 50
patients, respectively, with prostate sizes of >45 or <45 cm,3 there
was no signiﬁcant difference in complication rates between the
different operators (Tables 4 and 5).
4. Discussion
CaP has increased in Taiwan over the past decade. In 2007, there
were an estimated 3367 new cases in Taiwan, which made CaP the
ﬁfth leading cancer in men. There were 936CaP-related deaths in
2009, ranking seventh in cancer-related mortality in men.Operator p
3 4 5
27 (27) 34 (34) 41 (41) 0.175
40 (40) 39 (39) 38 (38) 0.798
13/52 (25) 12/56 (21.4) 11/51 (21.6) 0.904
18/42 (42.9) 22/41 (53.7) 30/49 (61.2) 0.358
10/49 (20.4) 10/42 (23.8) 10/49 (20.4) 0.972
29/49 (59.2) 26/48 (54.2) 26/47 (55.3) 0.958
Table 3
Cancer detection rate of the ﬁrst and last 20 patients (pts.).
Cancer detection rate Operator p
1 2 3 4 5
Overall
First 20 pts. (%) 11 (55) 7 (36) 5 (25) 4 (20) 8 (40) 0.159
Last 20 pts. (%) 6 (30) 13 (37) 8 (40) 12 (60) 9 (45) 0.156
First 20 biopsies
PSAw4e10 ng/dL cancer (%) 5/14 (35.7) 5/7 (71.4) 3/10 (30) 2/11 (18.2) 3/13 (23.1) 0.167
PSA > 10 ng/dL cancer (%) 6/6 (100) 5/12 (41.7) 2/8 (25) 2/7 (28.6) 4/7 (57.2) 0.046
Last 20 biopsies
PSAw4e10 ng/dL cancer (%) 3/14 (21.4) 5/10 (50) 2/11 (18.2) 2/6 (33.3) 3/10 (30) 0.527
PSA > 10 ng/dL cancer (%) 3/6 (50) 6/6 (100) 6/9 (66.7) 10/14 (71.4) 6/9 (66.7) 0.426
PSA ¼ prostate-speciﬁc antigen.
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sextant prostate biopsy has been the gold standard for diagnosing
CaP.1 Indications for a prostate biopsy are abnormal DRE ﬁndings,
serum PSA level >4 ng/mL, the presence of cellular atypia, or high-
grade prostatic intraepithelial neoplasia on a previous TRUS biopsy.
However, studies indicated that a single set of sextant biopsies may
miss clinically detectable CaP in up to 34% of men.2,3 Elabbady et al
demonstrated that an extended 12-core prostate biopsy increases
both the CaP detection rate and the accuracy of the Gleason score.4
Lawrentschuk et al reported a variation in CaP detection rates
among different operators.5 In total, 4724 initial TRUS-guided
prostate biopsies performed by four uroradiologists were studied,
and a signiﬁcant difference in CaP detection was seen among
operators who performed TRUS-guided prostate biopsies even in
the same setting.
In a study by Karam et al,6 residents at different training levels
showed no signiﬁcant difference in overall cancer detection rates,
DRE ﬁndings, or prostate volume measurements for patients with
PSA levels of approximately 4e10 ng/mL. However, limitations of
that study were a small number of prostate biopsies and multiple
residents at different levels of training.
The average cancer detection rate by TRUS biopsy of the prostate
was reported to be approximately 29e39.4%.6e10 End-ﬁre probe
and side-ﬁre probe cancer detection rates were studied, with
a signiﬁcant difference in overall cancer detection rates in the end-Table 4
First 20 and last 20 patients’ (pts.) complications by different operators and prostate
sizes of greater and less than 45 cm3.
Operator
1 2 3 4 5
Prostate < 45 cm3
First 20 pts. complications (%) 1 (5) 0 (0) 0 (0) 1 (5) 1 (5)
Last 20 pts. complications (%) 0 (0) 1 (5) 0 (0) 1 (5) 0 (0)
Prostate > 45 cm3
First 20 pts. complications (%) 2 (10) 2 (10) 1 (5) 0 (0) 0 (0)
Last 20 pts. complications (%) 1 (5) 1 (5) 0 (0) 0 (0) 0 (0)
Table 5
First 50 and last 50 patients’ (pts.) complications by different operators and prostate
sizes of greater and less than 45 cm3.
Operator
1 2 3 4 5
Prostate < 45 cm3
First 50 pts. complication (%) 3 (6) 0 (0) 0 (0) 1 (2) 1 (2)
Last 50 pts. complication (%) 0 (0) 1 (2) 1 (2) 1 (2) 0 (0)
Prostate > 45 cm3
First 50 pts. complication (%) 2 (4) 2 (4) 1 (2) 1 (2) 1 (2)
Last 50 pts. complication (%) 2 (4) 1 (2) 0 (0) 0 (0) 2 (4)versus side-ﬁre arms (45.8% vs. 38.5%, p < 0.001). In the subsets of
patients with PSA levels of approximately 4e10 and >10 ng/mL,
a signiﬁcant difference in the cancer detection rate persisted (46.4%
vs. 38.9% and 61.7% vs. 49.1%, p < 0.004 and <0.015, respectively).10
Therefore, we separated the patients into two groups of PSA levels
of approximately 4e10 and >10 ng/mL, so as to study individual
cancer detection rates.
In this study, we found no signiﬁcant differences among oper-
ators in overall CaP detection rates, even though they performed
different numbers of biopsies. We further compared the operators’
ﬁrst and last 20 and 100 prostate biopsies to evaluate whether
cancer detection rates varied as operators became skilled in this
procedure, because we believe maturation of this technique might
not require an excessive number of cases. We found that there was
a signiﬁcant difference in cancer detection rates among operators
for their ﬁrst 20 prostate biopsies in patients with PSA > 10 ng/mL
(p ¼ 0.046). However, the small numbers of biopsies in this group
(6, 12, 8, 7, and 7 biopsies by each operator) may have limited its
power. In addition, the great range of PSA levels (approximately
0.4e9442 ng/mL) in our patients may also have affected cancer
detection rates. Furthermore, the majority of patients in groups 1
and 5 had greater PSA (ﬁve and four patients had PSA levels>30 ng/
mL, respectively), which could explain the difference in cancer
detection rates by examining different groups of patients.
Prostate sizes of >45 cm3 were reported to increase the rate of
postbiopsy acute prostatitis and acute urinary retention.11 There-
fore, we compared the ﬁrst 20 and 50 with the last 20 and 50
patients, respectively, with prostate sizes of >45 and <45 cm3, and
found no signiﬁcant difference in complication rates among
different operators (Table 4).
There are several limitations of our study. This was a retrospec-
tive study, and the deﬁnition of complications was limited to
symptomatic UTIs requiring hospitalization and acute urinary
retention, and did not include minor complications, such as
hematuria and rectal bleeding.
5. Conclusions
Therewas no signiﬁcant difference in overall CaP detection rates
with different operators using TRUS-guided prostate biopsies. In
addition, there was no change in major complication rates with
greater experience. TRUS-guided prostate biopsy is a rapidly
learned technique and is a good diagnostic tool for detecting CaP.
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